Based on the current clinical and pathological prognostic indicators such as Tumor-Nodes-Metastases (TNM) staging, HER2/neu and hormonal receptor status, many early stage breast cancer patients receive unnecessary adjuvant treatment after the removal of a primary tumor [3]. Here, ERBB2 is linked to breast carcinoma.